Nus Esg S-Cp Grw

Medpace Holdings CEO Announces Sale of Common Stock

Barclays Raises nVent Electric Price Target, Stock Rises

Ionis Pharmaceuticals Director Sold Company Common Stock

Medpace CEO Sells Company Shares

Carpenter Technology's EVP and CFO Disposes of Company's Common Stock

Ionis Pharmaceuticals Receives FDA Breakthrough Therapy Designation

Abbott Announces $21 Billion Acquisition of Alere to Enhance Diagnostic Business

Ionis Pharmaceuticals Director Disposes of Company Common Stock

Ionis Pharmaceuticals EVP and CHRO Shannon L. Devers Sells Common Stock

Abbott Acquires Exact Sciences for $21 Billion in Cash

Edmond de Rothschild Holding Increases Stake in nVent Electric PLC

nVent Electric VP Exercises Stock and Pays Option Fees

Medpace Holdings EVP Susan E. Burwig Reports Sale of Common Stock

Medpace Holdings Hits New 52-Week High and Reports Strong Quarterly Earnings

Carpenter Technology Completes $700M Private Placement and Amends Credit Agreement

nVent Electric Director Greg Scheu Sells Company Common Stock

Medpace CEO August J. Troendle Disposes of Common Stock

Medpace VP Files Form 144 to Prepare for Sale of 20,000 Restricted Shares

Jefferies Downgrades Exact Sciences Rating While Upgrading Price Target

nVent Electric plc CEO Sells Company Common Stock

SEVEN HILLS RLTY TR COM USD0.001 (S/R 04/12/2025)

SMX Security Matters

Polyrizon

Picard Medical

Synchronoss Tech

PharmaCyte Biotech

Q/C Tech

Rich Sparkle

Tradr 2X Long ASTS Daily ETF

Able View Global

IONS

Wender Joseph H, Director of Ionis Pharmaceuticals Inc, sold 28,000 shares worth $2.3 million on December 1, 2025, as disclosed in a Form 4 filing with the SEC. The sale was executed under a prearranged trading plan (10b5-1). After the sale, Wender holds 52,035 shares.

Reuters

Ionis Pharma

Dir Wender Sells 28,000 ($2.3M) Of Ionis Pharmaceuticals Inc [IONS]

Joseph H. Wender, Director at Ionis Pharmaceuticals Inc., reported selling common shares of the company. The filing is available via EDGAR, the SEC's system. This news is AI-generated by Public Technologies and is not financial advice.

Ionis Pharmaceuticals Director Joseph H. Wender Reports Sale of Common Shares

TechnipFMC PLC's stock rose 2.98% to $46.67, hitting a new 52-week high, but underperformed compared to competitors like Oil States International Inc., which rose 5.84%. Trading volume was below average.

Dow Jones

TechnipFMC

TechnipFMC PLC Stock Underperforms Wednesday When Compared To Competitors Despite Daily Gains

MEDP

Medpace Holdings Insider Sold Shares Worth $17,114,847, According to a Recent SEC Filing

marketscreener

Medpace

Medpace Holdings Insider Sold Shares Worth $17,114,847, According to a Recent SEC Filing

Medpace Holdings Inc.'s CEO, August J. Troendle, reported the disposal of common shares. This information was published via the U.S. SEC's EDGAR system. The news is generated by Public Technologies using AI and is for informational purposes only.

Medpace CEO August J. Troendle Reports Disposal of Common Shares

EWBC

Prudential Financial Inc. reduced its stake in East West Bancorp by 58.6% in Q2. Other investors adjusted their positions, with US Bancorp DE increasing its stake by 880.7%. Insiders sold shares, impacting stock ownership. East West Bancorp's stock opened at $107.15, with a market cap of $14.74 billion. Analysts expect an EPS of 8.85 for the year, with new price targets set by Citigroup and Barclays.

Market Beat

US Bancorp

Prudential financial

East West Bancorp

East West Bancorp, Inc. $EWBC Shares Sold by Prudential Financial Inc.

East West Bancorp, Inc. announced the appointment of Peter Babej as a director, effective December 1, 2025. He joins the Risk Oversight Committee and will receive compensation as per the company's non-employee director program. The board now has eleven directors, ten of whom are independent.

East West Bancorp, Inc. and East West Bank Announces Board and Committee Appointments, Effective December 1, 2025

Ionis Pharmaceuticals Inc. has received Breakthrough Therapy designation from the FDA for zilganersen, a treatment for Alexander disease. This designation is for therapies showing substantial improvement over existing treatments. Zilganersen showed significant results in a pivotal study, including stabilization of gait speed. Ionis plans to submit a New Drug Application in early 2026 and start an Expanded Access Program in the U.S. There are no approved treatments for Alexander disease currently.

FDA Grants Breakthrough Therapy Designation to Ionis Pharmaceuticals' Zilganersen for Alexander Disease

Shareholder Wender Joseph H Trust filed a Form 144 to sell 14,479 shares of Ionis Pharmaceuticals Inc [IONS] on December 1, 2025, through Goldman Sachs & Co. The sale is executed under a prearranged trading plan (10b5-1).

Shareholder Wender Joseph H Trust Files To Sell 14,479 Of Ionis Pharmaceuticals Inc [IONS]

Medpace Holdings Insider Sold Shares Worth $34,074,470, According to a Recent SEC Filing

Medpace Holdings Insider Sold Shares Worth $34,074,470, According to a Recent SEC Filing

Troendle August J Chairman of the Board of Medpace Holdings Inc [MEDP] filed a Form 4 on December 1, 2025 with the Securities and Exchange Commission disclosing the following changes in ownership:Date11/26/25-11/28/25TransactionSaleShares56,482Price$603.28Value$34,074,472Ending Holdings: 5,408,747 (675,728 - Direct, 4,733,019 - Indirect) For a free trial, or to learn more about our insider trading analysis and data services, please visit or contact us at (301) 913-5100 or send an email to info@washingtonservice.com.Founded in 1970, The Washington Service provides securities professionals with financial, economic and public policy research and data.

Chmn Troendle Sells 56,482 ($34.1M) Of Medpace Holdings Inc [MEDP]

Medpace CEO August J. Troendle has reported the sale of common shares of Medpace Holdings Inc. This information was disclosed through a filing accessible via EDGAR, the SEC's system. The news brief was generated by Public Technologies using AI and is not financial advice.

Medpace CEO August J. Troendle Reports Sale of Common Shares

East West Bancorp Inc. has filed an initial statement of beneficial ownership with the U.S. SEC, listing Peter Babej as a beneficial owner in his role as Director. This filing is accessible via EDGAR, the SEC's electronic system. The information was published by East West Bancorp Inc. on December 1, 2025, and is for informational purposes only.

East West Bancorp Inc. Files Initial Beneficial Ownership Statement for Director Peter Babej